EHA 2023 | Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL
Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, shares the findings of the follow-up of the EPCORE NHL-1 study (NCT03625037) evaluating subcutaneous epcoritamab in patients with relapsed/refractory (R/R) large B-cell lymphoma (LCBL). The data from this trial shows that epcoritamab induces durable complete responses (CR) with improved outcomes and a tolerable toxicity profile. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
The epcoritamab study is a fascinating one. We were able to achieve long-lasting and durable remissions in a difficult large B-cell lymphoma population, including high-grade lymphomas, grade 3B follicular lymphomas, grade zone lymphomas and the others. Now, at present, we had the update and we presented the data of the patients who achieved a complete regression, and those were 63 out of 157, so a considerable amount of them...
The epcoritamab study is a fascinating one. We were able to achieve long-lasting and durable remissions in a difficult large B-cell lymphoma population, including high-grade lymphomas, grade 3B follicular lymphomas, grade zone lymphomas and the others. Now, at present, we had the update and we presented the data of the patients who achieved a complete regression, and those were 63 out of 157, so a considerable amount of them. And the longer results are still fascinating, most of the patients being in a complete CR. Of notice, it should be, that the latest PR to CR conversion we observed at 72 months. However, the majority of patients started response one and a half months after initiation of therapy, and the median time to achieving a complete response, or the best response, was less than three months.
The long-term epcoritamab infusions resulted in few adverse events, although it should be noted that we lost eight out of those 157 patients due to COVID infections, and those should be really looked for, actively. We reckon that active seeking for asymptomatic infections is the key to success to keep the mortality in a normal range.
Read more...
